• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
【24h】

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas

机译：EGFR突变和ALAL重新排列对切除肺癌患者长期结果的预后意义

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To investigate the prognostic impact of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement for the overall survival (OS) of patients with surgically treated lung adenocarcinomas. A total of 689 patients with stage I-III lung adenocarcinomas (male:female = 334:355; median age, 64?years) underwent complete surgical resection between 2007 and 2013. The prognostic impact of EGFR mutation and ALK rearrangement on OS was analyzed using Cox regression analysis. Certain clinicopathological prognostic factors (i.e., age, sex, smoking status, nodule type, solid portion size, pathologic stage, adenocarcinoma subtype, and history of adjuvant chemotherapy) were included for adjustments of the hazard ratio (HR). EGFR mutation was observed in 438 patients (64%) and ALK rearrangement was seen in 28 patients (4%). Multivariable-adjusted Cox regression demonstrated that the prognostic effect of EGFR mutation on OS differed by age (HR, exp.[-5.199?+?0.064* age]). The adjusted HR for EGFR mutation was 0.14 (95% CI: 0.05-0.36; P??0.001) at 50?years, 0.26 (95% CI: 0.15-0.46; P??0.05). EGFR mutation was independently prognostic of the long-term outcomes of patients with surgically treated lung adenocarcinomas. A more favorable prognostic effect was seen in younger than in older patients. ALK rearrangement was not associated with OS. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：为了探讨表皮生长因子受体（EGFR）突变和包血性淋巴瘤激酶（ALK）对患者的整体存活（OS）的预后抗冲击患者的预后抗冲击患者的肺腺癌患者的整体存活率。共有689例患者I-III型肺腺癌（男性：女性= 334：355;中位年龄，64岁，64岁）在2007和2013年之间进行了完全的手术切除。分析了EGFR突变和ALK重排对OS的预后影响使用COX回归分析。包括某些临床病理学预后因子（即，年龄，性别，吸烟状态，结节型，固体部分大小，病理阶段，腺癌亚型和佐剂化疗的历史）用于调整危害比（HR）。在438名患者（64％）中观察到EGFR突变，28例患者（4％）中看到ALK重排。多变量调整的Cox回归证明EGFR突变对OS的预后作用依次不同（HR，EXP。[ - 5.199？+ 0.064 *年龄）。 EGFR突变的调节的HR为0.14（95％CI：0.05-0.36; p？<0.001），0.26（95％CI：0.15-0.46; p ?? 0.05）。 EGFR突变独立地预后患者的手术治疗肺腺癌的长期结果。比老年患者在较年轻的患者中看到了更有利的预后效果。 ALK重排未与OS相关。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号